Epirubicin and doxorubicin in advanced breast cancer: A comparative evaluation of epirubicin and doxorubicin Journal Article

  


Author: Casper, E. S.
Article Title: Epirubicin and doxorubicin in advanced breast cancer: A comparative evaluation of epirubicin and doxorubicin
Abstract: A clinical trial to compare the relative therapeutic and cardiotoxic effects of epirubicin and doxorubicin in patients with advanced breast cancer is presented. Patients had received prior cytotoxic chemotherapy, but none had received prior anthracycline treatment. Fifty-two evaluable patients received at random either epirubicin 85 mg/m2 or doxorubicin 60 mg/m2, intravenously every three weeks. Response rates were identical, with partial responses being achieved in six of the 24 patients treated with epirubicin and seven of 28 patients treated with doxorubicin. Median duration of response to epirubicin was almost 12 months compared to seven months in patients treated with doxorubicin. The trial was designed so that equivalent degrees of myelosuppression were achieved with each drug. Overall, epirubicin was better tolerated than doxorubicin and was less cardiotoxic. These findings indicate that epirubicin has therapeutic activities similar to that of doxorubicin with reduced toxicity.
Keywords: cancer chemotherapy; clinical article; controlled study; clinical trial; doxorubicin; breast cancer; randomized controlled trial; cardiotoxicity; epirubicin; drug toxicity; drug tolerance; human; female
Journal Title: Clinical Trials Journal
Volume: 24
Issue: Suppl. 1
ISSN: 0009-9325
Publisher: Elsevier B.V.  
Date Published: 1987-01-01
Start Page: 139
End Page: 141
Language: English
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023554198&partnerID=40&md5=08cf853d43d0828504dd3992bf7ca40c
Notes: Article -- Export Date: 5 February 2021 -- Source: Scopus